what structural features are required for allergens and how IgE, particularly anaphylactic IgE, is produced. However, the last few years have seen a flurry of new studies on IgE-independent mast cell activation, particularly via Mrgprb2 (mouse) and MRGPRX2 (human). These studies have greatly advanced our understanding of how mast cells exert non-histaminergic itch, pain, and drug-induced pseudoallergy by interacting with sensory neurons. Recent studies have also characterized mast cell activation and regulation by interleukin-33 (IL-33) and other cytokines and by non-coding RNAs. These newly identified mechanisms for mast cell activation and regulation will further stimulate the allergy/immunology community to develop novel therapeutic strategies for treatment of allergic and non-allergic diseases.
Introduction
Mast cells (MCs) play a crucial role in allergic reactions and the host defense against certain parasites, bacteria, and venoms. Morphologically, MCs are featured by a large number of secretory granules containing various bioactive molecules, including histamine, serotonin, proteoglycans, and proteases. Upon encounter with multivalent antigen (or allergen), antigen-specific immunoglobulin E (IgE)-bound high-affinity IgE receptors (FcεRI) on the surface of MCs are cross-linked or aggregated. Consequently, activation of the FcεRI signaling system is triggered, leading to the release of granular contents (degranulation) and de novo synthesis and secretion of lipid mediators, cytokines, and chemokines. Activation of MCs entails immediate hypersensitivity and late-phase allergic inflammation. With regard to the IgE-mediated MC activation, recent years have seen a deeper understanding of IgE synthesis, structural features of allergens, FcεRI signaling mechanisms, and counter-mechanisms. Non-IgE-dependent MC activation mechanisms have been studied at a slow pace for many years. However, we have witnessed significant progress in this area more recently.
Murine MCs are classified as connective tissue MCs (CTMCs) and mucosal MCs (MMCs) on the basis of their tissue distribution. CTMCs and MMCs are also characterized by the heparin content of their granules: CTMCs contain a large amount of heparin in their granules, whereas MMCs have very little or no heparin. Human MC proteases include tryptases (mMCP-6 and -7 in mouse), chymases (mMCP-1, -2, and -4), an elastase (mMCP-5), and a carboxypeptidase-A3 (CPA3). Human MCs are categorized by expression of MC tryptase (MC T ) or MC chymase (MC C ) or both (MC TC ) 1 . A recent transcriptional analysis demonstrated that the MC is one of the most transcriptionally variable cell types of the immune system 2 . Murine MCs that were purified from different tissues shared an "MC-specific" transcriptional signature of at least 100 genes. Also, these MCs showed a tissue-specific regulation of their transcriptomes.
Substantial progress has recently been made in several areas of MC research, such as degranulation machinery, cancer, microbiota, and food allergy. Readers interested in these topics are referred to recent review articles [3] [4] [5] [6] [7] [8] .
Allergen, immunoglobulin E, and FcεRI
A comprehensive understanding of the IgE-mediated MC activation requires a better knowledge of allergens, IgE synthesis and structure, and FcεRI structure and signaling pathways. Here, we highlight recent advances in this area, particularly allergens and IgE synthesis. We certainly know three-dimensional structures of many parts of IgE and FcεRI (composed of an IgE-binding α and receptor-stabilizing and signal-amplifying β and activation signal-triggering γ subunits) 9,10 and important principles in signaling, such as tyrosine phosphorylation of β and γ subunits at the immunoreceptor tyrosine-based activation motif (ITAM) by Src family kinases, the essential functions of Syk, Ca 2+ flux, several adaptor molecules, mitogenactivated protein kinases (MAPKs), and several transcription factors 11, 12 .
However, we feel obliged to note that our understanding of FcεRI signaling pathways is still in the early stages in light of an incomplete understanding of degranulation processes and a large number of genes regulated by MC activation.
One of the most important hypotheses on structural features of allergens stemmed from the requirement of cross-linking of cell surface IgE molecules by various allergens for MC activation and IgE synthesis. This line of thinking led Jensen-Jarolim et al. to recognize that allergens display repetitive motifs, which they designate allergen-associated molecular patterns 13, 14 . Indeed, many allergenic molecules occur as dimers or multimers. Some allergens-small proteins, in particular-have just a single immunodominant B-cell epitope and thus do not fulfill the requirement for cross-linking as a single molecular unit. Oligomerization provides the necessary means for efficient IgE cross-linking. Examples where only single dominant epitopes have been found are the allergens Der p 1 from house dust mite (HDM) and Bet v 1 from birch. Also, the occurrence of repetitive epitopes on single native allergen molecules has been shown on high-molecular-weight proteins of wheat and for HDMs and insects, cockroach Bla g 1, latex Hev b 5, and tropomyosin from shrimp.
IgE concentrations in serum are kept to the lowest level among immunoglobulin subtypes by several layers of regulation: in addition to the high rate of turnover, low efficiency of classswitch recombination to IgE, and lower surface expression of membrane IgE than that of IgG1 on germinal center (GC 
Mast cell activation by interleukin-33
IL-33 belongs to the IL-1 family and is expressed by several cell types, including epithelial cells [30] [31] [32] [33] . IL-33 binds to a specific receptor called T1/ST2 (ST2) that belongs to the Toll-like receptor/IL1R family. ST2 forms heterodimers with the IL-1 receptor accessory protein (IL-1RAcP), namely a transmembrane form (ST2 or ST2L) and a soluble form (sST2). ST2L isoform is expressed on MCs, basophils, Th2 cells, and natural killer cells and coordinates spatially and temporally with IL-33 signaling, which might trigger a key regulatory amplification loop involved in immune homeostasis. IL-33 is considered an alarmin as it is released after necrosis or tissue damage. However, apoptosis leads to the inactivation of IL-33 by cleavage of IL-33 by caspases. In contrast, MC serine proteases cleave the full-length IL-33 (IL-33 1-270 ) and liberate active forms: IL-33 95-270 , IL-33 , and IL-33 . These cleaved forms have 10 times greater potency than the full-length protein 34 . MC chymase also degrades IL-33 that leads to higher bioactivity 35 . Downstream of ST2, the IL-33-mediated ®signaling pathway involves MyD88, IRAK1, IRAK4, and TRAF6 as well as activation of MAPKs (ERK1/2, p38, and JNK1/2) and nuclear factor-kappa B (NF-κB) 36,37 .
IL-33 can induce full activation of MCs, including degranulation 38 and production of several cytokines and chemokines 39 , and elicits systemic MC-dependent anaphylaxis 38 . Several studies have shown that IL-33 plays a significant role in severe asthma 40 and refractory nasal polyposis 41 . Earlier studies have been summarized in excellent reviews [42] [43] [44] . Here, we touch on newer reports that showed a possible role of IL-33 in various allergic conditions: IL-33-mediated airway constriction was exacerbated through increased secretion of serotonin from MCs 45 . Staphylococcus aureus-derived serine protease-like protein (Spl) D is a potent allergen and induces a Th2-biased inflammatory response in the airways in an IL-33-dependent manner 46 . Aspirin-exacerbated respiratory disease (AERD) is a severe eosinophilic disorder of the airways and is characterized by overproduction of cysteinyl leukotrienes, activation of airway MCs, and bronchoconstriction in response to non-selective cyclooxygenase inhibitors that deplete prostaglandin E 2 (PGE 2 ) (Figure 1) . A study using clinical samples and mice deficient in PGE 2 synthase (a model of AERD) found up-regulation of IL-33 in airway epithelium 47 . Deletion of leukotriene C4 synthase in the AERD model mice eliminates the increased IL-33, lung eosinophilia, and aspirin-induced MC activation and bronchoconstriction. MCs have been shown to play a crucial role in a model of skin inflammation by IL-33-mediated recruitment of leukocytes and resulting inflammation in an MK2/3 (MAPK-activated protein kinases 2 and 3)-dependent manner 48 . In a murine model of food allergy, IL-33 and MCs promote inflammation in the gastrointestinal tract through IL-4 production by IL-33-stimulated ILC2s, as IL-4 blocks the generation of allergen-specific regulatory T (Treg) cells [49] [50] [51] . mRNA and protein expression of MRGPRX2 and its function 79 . MCs are also required for cardiac fibrosis in multiple animal models. Interestingly, NK-1R expression in MCs is not required in cardiac fibrosis 80 . It should be tested whether Mrgprb2 is involved in this process.
MicroRNA and mast cell biology
MicroRNA (miRNA), a small non-coding RNA molecule that is 19 to 25 nucleotides in length, functions in post-transcriptional regulation and RNA silencing of gene expression. miRNAs work by base pairing with complementary sequences inside of mRNA molecules. Because of the broad regulatory mechanisms, miRNAs regulate differentiation, proliferation, survival, apoptosis, stress response, and the effector function as well as the resolution of an immune response 81, 82 .
Numerous studies have examined the role of miRNAs in MC biology (Table 1) 83
. Silencing of Dicer, a key enzyme of miRNA biogenesis, attenuates degranulation, indicating that miRNAs are involved in MC activation. Overexpression of miR-142-3p, which rescues Dicer expression, enhances FcεRI-mediated degranulation in MCs . MiR-221-3p, which is markedly increased in asthmatics, up-regulates IL-4 secretion from MCs by targeting phosphatase and tensin homolog (PTEN) as well as activation of p38 and NF-κB 98 . MiR-302e negatively regulates RelA/p65 expression in MCs and ameliorates allergic inflammation through inhibition of the NF-κB signaling pathway 99 . MiR-143 and miR-146 reduce MC activation by targeting IL-13Rα1 and TRAF/IRAK, respectively, leading to a reduced allergic response [100] [101] [102] [103] . miR-20a inhibits expression of tumor necrosis factor (TNF), IL-1β, and interferon gamma (IFN-γ) while promoting IL-10 in HMC-1 human MCs. miR-20a also targets histone deacetylase 4 (HDAC4), which contributes to the epigenetic regulation of IL-10 expression 104 .
Shefler et al. showed that MCs are activated by interaction with activated T cells or their microvesicles (mvT*s) 105, 106 . The physical contact of MCs with activated T cells or with mvT*s induces Ras activation and ERK phosphorylation, leading to degranulation and release of several cytokines in MCs [106] [107] [108] [109] [110] . The same group later found that miR-4443 in mvT*s targets the expression of protein tyrosine phosphatase receptor type J (PTPRJ), a known ERK inhibitor 111 . Several miRNAs that play a role in cancer have recently been discovered: miR-9 increases the invasion of neoplastic MCs
112
. miR-122 targets SOCS1 mRNA and regulates cellular interactions involving cancer cells, MCs, and macrophages during allergic inflammation 113 . Exosomal miRNAs have emerged as mediators of the interaction between MCs and tumor cells. MCs can inhibit hepatocellular carcinoma cell metastasis by inhibiting the ERK1/2 pathway by transferring the exosomal shuttle microRNAs, including miR-490, into hepatocellular carcinoma cells 114 .
Perspectives on mast cells in diseases
Traditionally, MCs have been implicated in allergic diseases. Efficacy of omalizumab-humanized anti-IgE monoclonal antibody (mAb)-and mAbs targeting Th2 cytokines or Th2 cytokine receptors for the treatment of asthma and other allergic diseases supports crucial pathogenic roles for MCs in these diseases [115] [116] [117] . Among the mAbs targeting cytokine/receptors, the most illustrative example is dupilumab (mAb for IL4Rα, the subunit shared by IL-4 and IL-13 receptors). This mAb blocks the functions of both IL-4 and IL-13 and is highly efficacious for the treatment of atopic dermatitis 118 and asthma 119, 120 . However, effects of dupilumab likely reflect pleiotropic functions of IL-4 and IL-13 in immune and non-immune cells.
MCs are considered an important player in inflammation-associated diseases in general, as recent studies have extended their potential role in other diseases. For example, MCs seem to be involved in gastrointestinal diseases such as inflammatory bowel disease, celiac disease, and irritable bowel syndrome 121 . The phenotype and the activation status of MCs rather than the absolute numbers in the intestinal mucosa are important for the development and progression of the diseases 122 . MCs might also play a role in atherosclerosis. Immunohistochemical studies in autopsied human subjects and studies in murine atherosclerotic models have collectively provided evidence that the compounds released by activated MCs might promote atherogenesis at various stages during the development of atherosclerotic lesions
123
. MCs can be pro-tumorigenic and anti-tumorigenic 4, 124 . A recent study found that immune cells such as MCs, tumor-associated neutrophils, tumor-infiltrating macrophages, and myeloid-derived suppressor cells promote prostate cancer via various types of intercellular signaling 125 . With regard to neural diseases, MCs might contribute to modulate the intensity of the associated depressive and anxiogenic component on the neuronal and microglial biological front 126 . Preclinical evidence suggests that the intestinal microbiota contributes significantly to behavioral and mood disorders. Microbiotic conditions have been linked to pain, anxiety, stress, and depression in humans 126 . Far from being substantiated by other studies, symptoms of autism spectrum disorder might also be caused by the mediators derived from MCs which could activate microglia, causing localized inflammation 127 . MCs might play a significant role as a neuroimmune connection between these components. The next decade might see unexpected developments in MC research and their clinical translations.
